The global GLP-1 receptor agonist market is poised for remarkable expansion in the coming decade, according to a recent market analysis. Projections suggest an impressive surge from US$ 23,854.53 ...

With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...

The researchers treated cancer cells with a combination of venetoclax, a current standard-of-care drug for AML, and a STING ...

Palatin Technologies (PTN) stock gains as the FDA clears a study to test its obesity therapy bremelanotide, with Eli Lillys ...

With the FDA greenlighting its investigational new drug (IND) application, the company is eyeing a mid-2024 timeline to begin ...

DD01 is a long-acting dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors. The designation was based on data from a randomized, double-blind, placebo-controlled phase 1 study ...

"The conclusion of enrollment for Regimen G marks a critical step forward for the HEALEY ALS platform Trial," said Drs. Paganoni and Babu. "We extend our thanks to Denali, academic collaborators, and ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal second quarter 2024 ...

Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid ...

A first-in-class interleukin (IL)-15 receptor agonist, the drug is specifically approved in combination with BCG for adults ...

There are more than 50 glucagon-like peptide-1 receptor agonists (GLP-1RAs) in clinical development for Type 2 diabetes, ...

ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) ...